With new, innovative arthritis medications coming to market, patients with arthritis may soon have access to potentially less expensive biosimilar medications (similar to biologics).
However, imagine that, without your knowledge, your pharmacy substituted the biologic medication prescribed by your doctor with a new interchangeable biosimilar. Residents of Arizona no longer have to worry because this week, Arizona Governor Doug Ducey signed House Bill 2310 (HB 2310) into law. HB 2310 allows pharmacists to substitute biologic medications with new, interchangeable and potentially less expensive biosimilar medications when they come to market. The bill also ensures patients and their physicians know when a substitution occurs, resulting in a complete and accurate patient medical record. And, if physicians do not want a substitution to occur, they can stipulate that the prescription be dispensed as written.
Continue reading Arizona Arthritis Advocates Achieve Biosimilar Substitution Victory!
Big news for our arthritis community in Kentucky! On April 13, 2016, Gov. Matt Bevin (R – KY) signed Senate Bill 134 into law. The law creates a pathway for the introduction and use of biosimilars into the mainstream marketplace. Biosimilar medications have the potential to provide safe and effective treatment to people with arthritis at a potentially lower cost than name-brand biologic medications.
The many letters, calls and visits made by Arthritis Foundation Advocates in Kentucky played a significant role in the passage of SB 134.
Continue reading Advocates in Kentucky Get a Big Win for Biosimilar Substitution
Today we celebrate a huge victory for the arthritis community in New Jersey! New Jersey’s Governor, Chris Christie, has signed into law Assembly Bill 2477, a bill that allows biosimilar medications to become available for people with arthritis and other chronic diseases.
AB-2477 creates a pathway for biosimilars to enter the market place, potential for the development of new and innovative medications, and improves access to additional treatment options for people currently relying on biologics. Unlike other generic drug alternatives, biosimilars are developed from proteins in living cells and are highly similar to biologic medications.
Continue reading Arthritis Foundation Advocates Achieve Legislative Victory in New Jersey – Biosimilars Become Available!
Recently, the Arthritis Foundation lead the charge in the passage of three new laws in the state of California that will ensure patient care and continue to keep prescription costs low. The laws focused on issues dealing with Biosimilar Substitution, Step Therapy, and controlling out-of-pocket costs for residents of California.
With specific regard to the new legislation regulating the step therapy process, Krystin Herr, vice president of government affairs and advocacy in the pacific region for the Arthritis Foundation, stated, “Many patients with complex chronic conditions, such as rheumatoid arthritis, do not always fit a ‘one size fits all’ approach to medication. However, step therapy protocols do not reflect that.”
Continue reading Arthritis Foundation Advocates Help Achieve 3 Big Victories in California!
Today, we celebrate our tremendous Advocates and a fantastic victory! The FDA has issued proposed guidance to require unique names for biosimilar products that have submitted applications to the FDA.
The Arthritis Foundation and our team of 125,000 advocates have advocated for distinguishable names to ensure patient safety is given the highest priority. Unlike generic medications, biosimilars are not necessarily exact copies of brand name biologics. The change will lessen confusion among prescribers, allow for transparency in notification and drug substitution, strengthen patient adverse reaction tracking and make data collection easier.
Continue reading A Big Win For Arthritis Foundation Advocates: FDA Proposal Would Require Unique Names for Biosimilars
Thanks in large part to the many letters, calls and visits made by Arthritis Foundation Advocates in Illinois, on July 30, Gov. Bruce Rauner (R – IL) signed Senate Bill 455 into law.
The law creates a pathway for the introduction and use of biosimilars into the mainstream marketplace. Biosimilar medications have the potential to provide safe and effective treatment to people with arthritis at a potentially lower cost than name-brand biologic medications.
Biologics are carefully engineered, and they can never truly be duplicated. This means that even biosimilars deemed interchangeable are not generic replicas of original biologics. Nationwide, states are now enacting legislation to create a pathway for biosimilars because current laws on generic substitution do not have jurisdiction on biosimilars.
Continue reading Advocates in Illinois Get a Big Win for Biosimilars